Glaxosmithkline Phar

₹3283.7 -14.6 | 0.4%

WEBSITE BSE:500660 NSE : GLAXOSMITH 04 Jul, 15:57

Market Cap ₹55628 Cr.

Stock P/E 60

P/B 28.3

Current Price ₹3283.7

Book Value ₹ 116.1

Face Value 10

52W High ₹3516

Dividend Yield 1.64%

52W Low ₹ 1924.3

Edit Ratio

Glaxosmithkline Phar Research see more...

Overview Inc. Year: 1924Industry: Pharmaceuticals & Drugs

GlaxoSmithKline Pharmaceuticals Ltd is a pharmaceutical enterprise. The Company is engaged in the business of manufacturing, distributing, and trading in prescription drugs. It manufactures medicinal materials used in the manufacture of prescription drugs, inclusive of antibiotics, endocrine products, basic nutrients; opium derivatives; sulpha tablets; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically natural sugar. It gives various prescription drugs, vaccines, and consumer healthcare products. Its medication portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio consists of Ambirix, Cervarix, Fendrix, and Havrix. The Company's products consist of Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health merchandise include Sensodyne, parodontax and Polident. Its manufacturing unit is at Nashik.

Glaxosmithkline Phar Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Glaxosmithkline Phar Quarterly Results

#(Fig in Cr.)	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Net Sales	802	787	762	957	805	930	815	1011	949	974
Other Income	23	28	36	28	28	30	36	35	35	41
Total Income	826	815	798	985	833	960	850	1045	984	1015
Total Expenditure	574	618	618	668	587	673	584	689	658	641
Operating Profit	252	197	180	318	246	287	266	356	327	374
Interest	0	1	0	0	0	1	0	0	0	1
Depreciation	16	17	16	18	17	18	16	17	19	15
Exceptional Income / Expenses	-11	10	17	0	-163	2	0	5	0	0
Profit Before Tax	224	190	181	299	65	271	249	344	308	359
Provision for Tax	60	57	49	82	20	76	67	91	78	96
Profit After Tax	165	133	132	218	46	194	182	253	230	263
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	165	133	132	218	46	194	182	253	230	263
Adjusted Earnings Per Share	9.7	7.9	7.8	12.8	2.7	11.5	10.8	14.9	13.6	15.5

Glaxosmithkline Phar Profit & Loss

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Net Sales	3363	2838	2908	2871	3128	3224	2926	3278	3252	3454	3749	3749
Other Income	259	123	73	55	102	79	111	76	101	123	146	147
Total Income	3622	2961	2982	2926	3230	3303	3036	3354	3352	3576	3895	3894
Total Expenditure	2788	2360	2489	2366	2527	2567	2327	2516	2447	2545	2572	2572
Operating Profit	833	601	492	560	703	736	709	838	905	1031	1323	1323
Interest	0	0	0	0	1	6	4	2	2	2	1	1
Depreciation	25	25	26	38	49	83	79	68	66	70	67	67
Exceptional Income / Expenses	-52	2	46	18	29	-341	-173	12	-1	-144	5	5
Profit Before Tax	756	578	511	540	683	306	454	779	836	816	1260	1260
Provision for Tax	279	202	174	189	237	213	167	398	229	226	332	332
Profit After Tax	476	376	337	351	445	93	287	381	608	590	928	928
Adjustments	0	0	0	0	0	0	71	1314	3	0	0	0
Profit After Adjustments	476	376	337	351	445	93	358	1695	611	590	928	928
Adjusted Earnings Per Share	28.1	22.2	19.9	20.7	26.3	5.5	21.1	100	36	34.8	54.8	54.8

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	9%	5%	3%	1%
Operating Profit CAGR	28%	16%	12%	5%
PAT CAGR	57%	35%	58%	7%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	27%	29%	17%	7%
ROE Average	49%	37%	29%	23%
ROCE Average	68%	51%	44%	35%

Glaxosmithkline Phar Balance Sheet

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Shareholder's Funds	1829	2183	2007	2057	2140	1821	1478	2663	1741	1778	1951
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	3	2	1	1	0	0	0	0	0	0	0
Other Non-Current Liabilities	194	3497	3699	2632	2860	180	179	159	125	108	111
Total Current Liabilities	1107	784	881	2949	2804	1022	1355	1698	1326	1525	1905
Total Liabilities	3133	6465	6588	7639	7804	3023	3012	4520	3193	3410	3967
Fixed Assets	123	204	253	323	430	757	386	329	329	320	283
Other Non-Current Assets	423	3883	4500	3780	4015	491	423	483	370	292	274
Total Current Assets	2587	2372	1833	3531	3356	1775	2023	3708	2494	2798	3410
Total Assets	3133	6465	6588	7639	7804	3023	3012	4520	3193	3410	3967

Glaxosmithkline Phar Cash Flow

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Opening Cash & Cash Equivalents	95	115	115	139	201	99	105	405	286	35	64
Cash Flow from Operating Activities	338	139	234	473	409	490	578	811	484	582	1290
Cash Flow from Investing Activities	180	499	301	-104	-153	-57	418	-406	808	9	-46
Cash Flow from Financing Activities	-497	-638	-511	-307	-358	-428	-696	-524	-1543	-561	-769
Net Cash Inflow / Outflow	21	-0	24	62	-102	6	300	-119	-251	29	475
Closing Cash & Cash Equivalent	116	115	139	201	99	105	405	286	35	64	539

Glaxosmithkline Phar Ratios

#	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Earnings Per Share (Rs)	28.12	22.2	19.88	20.7	26.29	5.5	21.14	100.04	36.05	34.83	54.76
CEPS(Rs)	29.62	23.68	21.44	22.95	29.16	10.38	21.6	26.5	39.75	38.94	58.7
DPS(Rs)	62.5	50	30	35	20	40	30	90	32	32	54
Book NAV/Share(Rs)	107.96	128.88	118.46	121.44	126.31	107.47	87.26	157.19	102.89	105.47	116.06
Core EBITDA Margin(%)	16.56	16.85	13.97	16.76	19.21	19.55	19.14	21.2	24.73	24.01	28.56
EBIT Margin(%)	21.8	20.4	17.05	17.89	21.84	9.28	14.64	21.73	25.78	21.61	30.59
Pre Tax Margin(%)	21.78	20.38	17.04	17.89	21.82	9.09	14.53	21.67	25.72	21.57	30.56
PAT Margin (%)	13.73	13.25	11.23	11.62	14.24	2.77	9.19	10.59	18.69	15.59	22.5
Cash Profit Margin (%)	14.46	14.13	12.11	12.88	15.79	5.23	11.71	12.49	20.71	17.43	24.12
ROA(%)	15.44	7.84	5.16	4.93	5.77	1.72	9.52	10.11	15.76	17.87	25.15
ROE(%)	24.95	18.75	16.08	17.26	21.22	4.71	17.42	18.39	27.58	33.43	49.43
ROCE(%)	39.53	28.81	24.39	26.56	32.54	15.76	27.74	37.72	38.06	46.49	67.64
Receivable days	10.35	14.59	18.09	19.21	15.6	11.96	18.42	21.37	22.32	19.98	22.78
Inventory Days	38.01	57.97	57.89	55.98	57.56	52.62	60.14	54.91	55.82	47.5	44.57
Payable days	81.61	87.58	79.21	115.38	122.52	106.45	119.53	140.69	143.05	144.03	174.99
PER(x)	60.5	85.59	68.79	50.36	49.44	226.34	68.13	16.62	36.73	55.8	52.55
Price/Book(x)	15.76	14.75	11.54	8.59	10.29	11.59	16.51	10.58	12.87	18.42	24.79
Dividend Yield(%)	1.84	1.32	1.1	1.68	1.54	3.21	2.08	5.41	2.42	1.65	1.88
EV/Net Sales(x)	8	10.85	7.66	5.7	6.67	6.21	7.94	7.84	6.54	9.22	12.63
EV/Core EBITDA(x)	32.29	51.21	45.26	29.21	29.65	27.18	32.8	30.67	23.51	30.89	35.77
Net Sales Growth(%)	28.96	-15.61	2.49	-1.27	8.94	3.08	-9.27	12.05	-0.8	6.21	8.56
EBIT Growth(%)	6.23	-23.45	-11.64	5.62	26.49	-54.32	46.6	70.71	7.32	-2.41	54.18
PAT Growth(%)	-1.09	-21.05	-10.46	4.13	26.99	-79.07	208.21	32.55	59.58	-2.91	57.23
EPS Growth(%)	-1.09	-21.05	-10.46	4.13	26.99	-79.07	284.26	373.19	-63.97	-3.39	57.23
Debt/Equity(x)	0	0	0	0	0	0	0	0	0	0	0
Current Ratio(x)	2.34	3.03	2.08	1.2	1.2	1.74	1.49	2.18	1.88	1.84	1.79
Quick Ratio(x)	2	2.36	1.6	1.03	1.02	1.26	1.09	1.87	1.53	1.49	1.54
Interest Cover(x)	1612.26	1373.88	2045.74	2856.45	1232.59	49.26	129.56	391.29	462.54	454.77	960.03
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Glaxosmithkline Phar Shareholding Pattern

#	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Promoter	75	75	75	75	75	75	75	75	75	75
FII	2.29	2.28	2.41	2.5	2.92	3.48	4.02	4.36	4.5	4.52
DII	10.28	10.3	10.25	10.02	8.65	7.9	7.5	7.33	7.31	7.79
Public	12.43	12.43	12.35	12.49	13.43	13.62	13.48	13.3	13.19	12.69
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Promoter	12.71	12.71	12.71	12.71	12.71	12.71	12.71	12.71	12.71	12.71
FII	0.39	0.39	0.41	0.42	0.5	0.59	0.68	0.74	0.76	0.77
DII	1.74	1.74	1.74	1.7	1.46	1.34	1.27	1.24	1.24	1.32
Public	2.11	2.11	2.09	2.12	2.27	2.31	2.28	2.25	2.23	2.15
Others	0	0	0	0	0	0	0	0	0	0
Total	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94

Pros

Company has delivered good profit growth of 58% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 37%
Company is almost debt free.

Cons

Debtor days have increased from 144.03 to 174.99days.
Stock is trading at 28.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Glaxosmithkline Phar News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Glaxosmithkline Phar

Add Watchlist

Glaxosmithkline Phar Research see more...

Overview Inc. Year: 1924Industry: Pharmaceuticals & Drugs

Glaxosmithkline Phar Share Price

Alert Data

Quarterly Price

Peer Comparison

Glaxosmithkline Phar Quarterly Results

Glaxosmithkline Phar Profit & Loss

Growth Rates

Glaxosmithkline Phar Balance Sheet

Glaxosmithkline Phar Cash Flow

Glaxosmithkline Phar Ratios

Glaxosmithkline Phar Shareholding Pattern

Glaxosmithkline Phar News

IPO

Sharescart: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!

Enter Your Complaint